361 related items for PubMed ID: 9113619
1. Treatment and disease effects on short-term growth and adult height in children and adolescents with 21-hydroxylase deficiency.
Hauffa BP, Winter A, Stolecke H.
Klin Padiatr; 1997; 209(2):71-7. PubMed ID: 9113619
[Abstract] [Full Text] [Related]
2. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Völkl TM, Simm D, Beier C, Dörr HG.
Pediatrics; 2006 Jan; 117(1):e98-105. PubMed ID: 16396852
[Abstract] [Full Text] [Related]
3. Effect of the dose of oral hydrocortisone on growth rate during long-term treatment of children with salt losing congenital adrenal hyperplasia.
Ciaccio M, Montiveros C, Rivarola MA, Belgorosky A.
Medicina (B Aires); 2002 Jan; 62(6):551-4. PubMed ID: 12532689
[Abstract] [Full Text] [Related]
4. [Puberty and growth development in patients with a 21-hydroxylase defect].
Börger D, Willig RP.
Monatsschr Kinderheilkd; 1985 Nov; 133(11):828-33. PubMed ID: 2934617
[Abstract] [Full Text] [Related]
5. [Growth and adult height in patients with congenital adrenal hyperplasia].
Kolousková S, Zemková D, Snajderová M, Lebl J.
Cas Lek Cesk; 1995 Nov 01; 134(21):689-91. PubMed ID: 8556761
[Abstract] [Full Text] [Related]
6. Long-term steroid treatment and growth: a study in steroid-dependent nephrotic syndrome.
Simmonds J, Grundy N, Trompeter R, Tullus K.
Arch Dis Child; 2010 Feb 01; 95(2):146-9. PubMed ID: 20172895
[Abstract] [Full Text] [Related]
7. The relation of peripubertal and pubertal growth to final adult height in children with classic congenital adrenal hyperplasia.
Bomberg EM, Addo OY, Kyllo J, Gonzalez-Bolanos MT, Ltief AM, Pittock S, Himes JH, Miller BS, Sarafoglou K.
J Pediatr; 2015 Mar 01; 166(3):743-50. PubMed ID: 25557963
[Abstract] [Full Text] [Related]
8. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation.
Bonfig W, Pozza SB, Schmidt H, Pagel P, Knorr D, Schwarz HP.
J Clin Endocrinol Metab; 2009 Oct 01; 94(10):3882-8. PubMed ID: 19622620
[Abstract] [Full Text] [Related]
9. Final height of patients with classical congenital adrenal hyperplasia.
Aycan Z, Akbuğa S, Cetinkaya E, Ocal G, Berberoğlu M, Evliyaoğlu O, Adiyaman P.
Turk J Pediatr; 2009 Oct 01; 51(6):539-44. PubMed ID: 20196386
[Abstract] [Full Text] [Related]
10. Presence of magnetic resonance imaging abnormalities of the hypothalamic-pituitary axis is a significant determinant of the first 3 years growth response to human growth hormone treatment in prepubertal children with nonacquired growth hormone deficiency.
Zenaty D, Garel C, Limoni C, Czernichow P, Léger J.
Clin Endocrinol (Oxf); 2003 May 01; 58(5):647-52. PubMed ID: 12699449
[Abstract] [Full Text] [Related]
11. Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the Italian experience.
Brunelli VL, Russo G, Bertelloni S, Gargantini L, Balducci R, Chiesa L, Livieri C, De Sanctis C, Einaudi S, Virdis R, Saggese G, Chiumello G.
J Pediatr Endocrinol Metab; 2003 Mar 01; 16 Suppl 2():277-83. PubMed ID: 12729404
[Abstract] [Full Text] [Related]
12. Growth pattern and final height in 21-hydroxylase deficiency.
Bajpai A, Pandey RM, Kabra M, Menon PS.
Indian Pediatr; 2007 Oct 01; 44(10):771-3. PubMed ID: 17998577
[Abstract] [Full Text] [Related]
13. Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect.
Wit JM, Rekers-Mombarg LT, Cutler GB, Crowe B, Beck TJ, Roberts K, Gill A, Chaussain JL, Frisch H, Yturriaga R, Attanasio AF.
J Pediatr; 2005 Jan 01; 146(1):45-53. PubMed ID: 15644821
[Abstract] [Full Text] [Related]
14. Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens.
Rasat R, Espiner EA, Abbott GD.
N Z Med J; 1995 Aug 11; 108(1005):311-4. PubMed ID: 7644165
[Abstract] [Full Text] [Related]
15. Growth pattern of untreated boys with simple virilizing congenital adrenal hyperplasia indicates relative androgen insensitivity during the first six months of life.
Bonfig W, Schwarz HP.
Horm Res Paediatr; 2011 Aug 11; 75(4):264-8. PubMed ID: 21196707
[Abstract] [Full Text] [Related]
16. Growth patterns in the first three years of life in children with classical congenital adrenal hyperplasia diagnosed by newborn screening and treated with low doses of hydrocortisone.
Bonfig W, Schmidt H, Schwarz HP.
Horm Res Paediatr; 2011 Aug 11; 75(1):32-7. PubMed ID: 20714115
[Abstract] [Full Text] [Related]
17. GH treatment and its effect on bone mineral density, bone maturation and growth in short children born small for gestational age: 3-year results of a randomized, controlled GH trial.
Arends NJ, Boonstra VH, Mulder PG, Odink RJ, Stokvis-Brantsma WH, Rongen-Westerlaken C, Mulder JC, Delemarre-Van de Waal H, Reeser HM, Jansen M, Waelkens JJ, Hokken-Koelega AC.
Clin Endocrinol (Oxf); 2003 Dec 11; 59(6):779-87. PubMed ID: 14974922
[Abstract] [Full Text] [Related]
18. Non-classical 21-hydroxylase deficiency in infancy and childhood: the effect of time of initiation of therapy on puberty and final height.
Weintrob N, Dickerman Z, Sprecher E, Galatzer A, Pertzelan A.
Eur J Endocrinol; 1997 Feb 11; 136(2):188-95. PubMed ID: 9116914
[Abstract] [Full Text] [Related]
19. Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia.
Ng SM, Stepien KM, Krishan A.
Cochrane Database Syst Rev; 2020 Mar 19; 3(3):CD012517. PubMed ID: 32190901
[Abstract] [Full Text] [Related]
20. HYDROCORTISONE THERAPY AND GROWTH TRAJECTORY IN CHILDREN WITH CLASSICAL CONGENITAL ADRENAL HYPERPLASIA.
Bizzarri C, Improda N, Maggioli C, Capalbo D, Roma S, Porzio O, Salerno M, Cappa M.
Endocr Pract; 2017 May 19; 23(5):546-556. PubMed ID: 28225306
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
